TICKERNOMICS Sign up
Last Update: 2023-12-23 06:03:57
Context Therapeutics Inc. ( CNTX ) https://www.contexttherapeutics.com
1.12USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
CNTX
77.78%
SPY
30.72%
CNTX
0.00%
SPY
112.82%
CNTX
0.00%
SPY
201.04%
CNTX
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
16.13
-5.55
0.18
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.80
0.00
0.88
-92.94
0.00
0.25
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
3.86
-55.27
-58.58
0.00
Other Earnings and Cash Flow Stats:
Context Therapeutics Inc. ( CNTX ) Net Income TTM ($MM) is -18.69
Context Therapeutics Inc. ( CNTX ) Operating Income TTM ($MM) is -20.78
Context Therapeutics Inc. ( CNTX ) Owners' Earnings Annual ($MM) is 0.00
Context Therapeutics Inc. ( CNTX ) Current Price to Owners' Earnings ratio is 0.00
Context Therapeutics Inc. ( CNTX ) EBITDA TTM ($MM) is -20.76
Context Therapeutics Inc. ( CNTX ) EBITDA Margin is 0.00%
Capital Allocation:
Context Therapeutics Inc. ( CNTX ) has paid 0.00 dividends per share and bought back 0.0 million shares in the past 12 months
Context Therapeutics Inc. ( CNTX ) has reduced its debt by 0.101029 million USD in the last 12 months
Capital Structure:
Context Therapeutics Inc. ( CNTX ) Interest-bearing Debt ($MM) as of last quarter is 0
Context Therapeutics Inc. ( CNTX ) Annual Working Capital Investments ($MM) are 1
Context Therapeutics Inc. ( CNTX ) Book Value ($MM) as of last quarter is 18
Context Therapeutics Inc. ( CNTX ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Context Therapeutics Inc. ( CNTX ) has 21 million in cash on hand as of last quarter
Context Therapeutics Inc. ( CNTX ) has 4 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Context Therapeutics Inc. ( CNTX ) has 15 common shares outstanding as of last quarter
Context Therapeutics Inc. ( CNTX ) has 0 million USD of preferred stock value
Academic Scores:
Context Therapeutics Inc. ( CNTX ) Altman Z-Score is -3.83 as of last quarter
Context Therapeutics Inc. ( CNTX ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
Context Therapeutics Inc. ( CNTX ) largest shareholder is Clear Harbor Asset Management, LLC owning 36000 shares at 0.04 ($MM) value
Martin A Lehr(an insider) Bought 5823 shares of Context Therapeutics Inc. ( CNTX ) for the amount of $4891.32 on 2023-02-21
6.82% of Context Therapeutics Inc. ( CNTX ) is held by insiders, and 23.92% is held by institutions
Context Therapeutics Inc. ( CNTX ) went public on 2021-10-20
Other Context Therapeutics Inc. ( CNTX ) financial metrics:
FCF:-16.62
Unlevered Free Cash Flow:0.00
EPS:-1.47
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-127.82
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Context Therapeutics Inc. ( CNTX ) :
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.